NVO’s Encouraging Data From the Novel Obesity Drug Study Novo Nordisk announced encouraging data from a phase Ib/IIa study on subcutaneous amycretin, a novel unimolecular GLP-1 and amylin ...

The drugmaker’s shares jumped last Friday after its once-weekly shot of amycretin delivered as much as 22% weight loss in an early trial. That helped soothe investor nerves about Novo’s drug ...

This year's EC50 honorees include a young indigenous leader regenerating rainforests and securing food sovereignty for his community; an ice-core scientist, high-altitude mountaineer studying the ...

The company's pipeline includes promising candidates such as Amycretin, an oral GLP-1/Amylin co-agonist that has shown competitive weight loss percentages in early trials. Novo Nordisk is also ...

35,106 people played the daily Crossword recently. Can you solve it faster than others?35,106 people played the daily Crossword recently. Can you solve it faster than others? I Was Willing To Do ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

Novo Nordisk, a leading global healthcare company, announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...

The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment of obesity and type 2 diabetes ...